Boulos and Cooper Pharmaceuticals Pty Ltd

Ramizol®: A new treatment for Clostridium difficile associated disease

A new class of styrylbenzene antibiotics, Ramizol®, has been developed to target Clostridium difficile associated disease. The drug stays in the gastrointestinal tract and reaches high concentrations to yield a therapeutic effect, with benefits including low frequency of resistance.

SourceBoulos and Cooper Pharmaceuticals Pty Ltd·JournalThe Journal of Antibiotics·DateMay 18, 2016

Zolav®: A new antibiotic for the treatment of acne

Zolav®, a new antibiotic, shows promising results in treating acne by significantly reducing infection and redness. The treatment offers a low-risk alternative to current standard care, which includes isotretinoin with potential side effects.

SourceBoulos and Cooper Pharmaceuticals Pty Ltd·DateApr 8, 2016